About: Relugolix/estradiol/norethisterone acetate

An Entity of Type: combination drug, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Relugolix/estradiol/norethisterone acetate (RGX/E2/NETA), sold under the brand names Myfembree and Ryeqo, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and for moderate to severe pain associated with endometriosis. It contains relugolix (RGX), an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol (E2), an estrogen, and norethisterone acetate (NETA), a progestin. The medication is taken by mouth.

Property Value
dbo:abstract
  • Relugolix/estradiol/norethisterone acetate (RGX/E2/NETA), sold under the brand names Myfembree and Ryeqo, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and for moderate to severe pain associated with endometriosis. It contains relugolix (RGX), an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol (E2), an estrogen, and norethisterone acetate (NETA), a progestin. The medication is taken by mouth. The most common side effects of the medication include hot flushes, excessive sweating or night sweats, uterine bleeding, hair loss or thinning, and decreased interest in sex. RGX/E2/NETA was approved for medical use in the United States in May 2021, and in the European Union in July 2021. (en)
dbo:alternativeName
  • Myfembree, Ryeqo (en)
dbo:kegg
  • D12226
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 67383921 (xsd:integer)
dbo:wikiPageLength
  • 10198 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1107165853 (xsd:integer)
dbo:wikiPageWikiLink
dbp:atcPrefix
  • H01 (en)
dbp:atcSuffix
  • CC54 (en)
dbp:class
dbp:component
  • Estradiol (en)
  • Norethisterone acetate (en)
  • Relugolix (en)
dbp:dailymedid
  • Relugolix_and_estradiol (en)
dbp:kegg
  • D12226 (en)
dbp:legalEu
  • Rx-only (en)
dbp:legalUs
  • Rx-only (en)
dbp:routesOfAdministration
dbp:synonyms
  • RGX/E2/NETA; MVT-601 (en)
dbp:title
dbp:titlestyle
  • background:#ccccff (en)
dbp:tradename
  • Myfembree, Ryeqo (en)
dbp:type
  • combo (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdf:type
rdfs:comment
  • Relugolix/estradiol/norethisterone acetate (RGX/E2/NETA), sold under the brand names Myfembree and Ryeqo, is a fixed-dose combination hormonal medication which is used for the treatment of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and for moderate to severe pain associated with endometriosis. It contains relugolix (RGX), an orally active gonadotropin-releasing hormone antagonist (GnRH antagonist), estradiol (E2), an estrogen, and norethisterone acetate (NETA), a progestin. The medication is taken by mouth. (en)
rdfs:label
  • Relugolix/estradiol/norethisterone acetate (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License